ClinicaliQ Trial Snapshot
- A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy — Active Not Recruiting • Phase III • NCT05819866.
- Trial testing whether leriglitazone drug slows cerebral adrenoleukodystrophy progression in adult men.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy. Conditions: Cerebral Adrenoleukodystrophy (cALD) Interventions: Leriglitazone, Placebo Lead Sponsor: Minoryx Therapeutics, S.L. Planned Enrollment: 40 participants